134 related articles for article (PubMed ID: 29271393)
1. Long-term Survival Associated with Crizotinib in a Lung Cancer Patient with a Pulmonary Artery Embolism.
Shen Q; Dong XQ; Zhou JY
Chin Med J (Engl); 2018 Jan; 131(1):111-112. PubMed ID: 29271393
[No Abstract] [Full Text] [Related]
2. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.
Park J; Yoshida K; Kondo C; Shimizu J; Horio Y; Hijioka S; Hida T
Lung Cancer; 2013 Sep; 81(3):495-496. PubMed ID: 23891512
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment with ceritinib after crizotinib induced hepatitis.
Sassier M; Mennecier B; Gschwend A; Rein M; Coquerel A; Humbert X; Alexandre J; Fedrizzi S; Gervais R
Lung Cancer; 2016 May; 95():15-6. PubMed ID: 27040846
[TBL] [Abstract][Full Text] [Related]
4. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib-induced fatal fulminant liver failure.
van Geel RM; Hendrikx JJ; Vahl JE; van Leerdam ME; van den Broek D; Huitema AD; Beijnen JH; Schellens JH; Burgers SA
Lung Cancer; 2016 Mar; 93():17-9. PubMed ID: 26898609
[TBL] [Abstract][Full Text] [Related]
6. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
[TBL] [Abstract][Full Text] [Related]
7. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacology profile of crizotinib (Xalkori(®)Capsules) and clinical findings on this drug].
Nonaka S; Yamaguchi S; Nagasawa T; Tahara M
Nihon Yakurigaku Zasshi; 2013 Feb; 141(2):106-13. PubMed ID: 23391552
[No Abstract] [Full Text] [Related]
9. Crizotinib in the treatment of non-small-cell lung cancer.
Forde PM; Rudin CM
Expert Opin Pharmacother; 2012 Jun; 13(8):1195-201. PubMed ID: 22594847
[TBL] [Abstract][Full Text] [Related]
10. Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.
Guérin A; Sasane M; Wakelee H; Zhang J; Culver K; Dea K; Nitulescu R; Galebach P; Macalalad AR
Curr Med Res Opin; 2015 Aug; 31(8):1587-97. PubMed ID: 26029864
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer.
Blackhall F; Kim DW; Besse B; Nokihara H; Han JY; Wilner KD; Reisman A; Iyer S; Hirsh V; Shaw AT
J Thorac Oncol; 2014 Nov; 9(11):1625-33. PubMed ID: 25436797
[TBL] [Abstract][Full Text] [Related]
12. Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy.
Dudnik E; Siegal T; Zach L; Allen AM; Flex D; Yust-Katz S; Limon D; Hirsch FR; Peled N
J Clin Neurosci; 2016 Apr; 26():46-9. PubMed ID: 26677785
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.
Tartarone A; Gallucci G; Lazzari C; Lerose R; Lombardi L; Aieta M
Future Oncol; 2015; 11(14):2043-8. PubMed ID: 26198834
[TBL] [Abstract][Full Text] [Related]
14. ALK inhibitors: what is the best way to treat patients with ALK+ non-small-cell lung cancer?
Toyokawa G; Seto T
Clin Lung Cancer; 2014 Sep; 15(5):313-9. PubMed ID: 24984564
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
16. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
Gilbert JA
Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
[No Abstract] [Full Text] [Related]
17. Crizotinib as a personalized alternative for targeted anaplastic lymphoma kinase rearrangement in previously treated patients with non-small-cell lung cancer.
Guo L; Zhang H; Shao W; Chen B
Drug Des Devel Ther; 2015; 9():5491-7. PubMed ID: 26491259
[TBL] [Abstract][Full Text] [Related]
18. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Efficacy of Crizotinib in Advanced ALK Positive
Non-small Cell Lung Cancer].
Zhao J; Zhang K; Zhang L; Wang H
Zhongguo Fei Ai Za Zhi; 2015 Oct; 18(10):616-20. PubMed ID: 26483333
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment with alectinib after crizotinib-induced esophageal ulceration.
Yoneshima Y; Okamoto I; Takano T; Enokizu A; Iwama E; Harada T; Takayama K; Nakanishi Y
Lung Cancer; 2015 Jun; 88(3):349-51. PubMed ID: 25837798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
